CristinaCusinMD
Psychiatry • Boston, MADirector of Translational Studies in Depression at Massachuseets General Hospital. Assistant Professor in Psychiatry at Harvard Medical School.
Dr. Cusin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Nicolls Rd
Boston, MA 11794Phone+1 617-726-2066
Education & Training
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 2006 - 2010
University of Milan Faculty of MedicineClass of 1997
Certifications & Licensure
MA State Medical License 2009 - 2026- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression Start of enrollment: 2010 Nov 01
- Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression Start of enrollment: 2012 Apr 01
- Neurobiological Bases of Placebo Response in Major Depressive Disorder Start of enrollment: 2012 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 63 citationsKetamine-Associated Brain Changes: A Review of the Neuroimaging Literature.Dawn F. Ionescu, Julia M. Felicione, Aishwarya Gosai, Cristina Cusin, Philip Shin
Harvard Review of Psychiatry. 2018-11-01 - 21 citationsStudying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.Valerie J. Sydnor, Amanda E. Lyall, Suheyla Cetin-Karayumak, Joey C. Cheung, Julia M. Felicione
Translational Psychiatry. 2020-12-15 - 26 citationsThe allopregnanolone to progesterone ratio across the menstrual cycle and in menopause.Allison Kimball, Laura E. Dichtel, Maren Nyer, David Mischoulon, Lauren B. Fisher
Psychoneuroendocrinology. 2020-02-01
Journal Articles
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Press Mentions
Atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine TreatmentNovember 17th, 2022- Placebo Effect Large in Treatment-Resistant DepressionSeptember 30th, 2021
- Low Doses of Nitrous Oxide May Treat DepressionJune 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
